Associated Genetic Biomarkers
Cyclin A2 (CCNA2) is a gene that encodes a member of the cyclin family that functions as a regulator of cyclin-dependent kinases (CDKs). Cyclin A2 is expressed in all tissues. Missense mutations, nonsense mutations, silent mutations, and frameshift deletions are observed in cancers such as cervical cancer, endometrial cancer, and intestinal cancer.
CCNA2 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains CCNA2 status as an inclusion criterion, 1 is phase 2 (1 open).
Trials with CCNA2 status in the inclusion eligibility criteria most commonly target malignant solid tumor .
The most frequent alteration to serve as an inclusion eligibility criterion is CCNA2 Mutation .
Abemaciclib is the most frequent therapy in trials with CCNA2 as an inclusion criteria .
Significance of CCNA2 in Diseases
Malignant Solid Tumor +
CCNA2 is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains CCNA2 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.